Development of Radiation/Nuclear Medical Countermeasures (MCMs) And Biodosimetry Devices
ID: BAA-75N93024R00020Type: Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NIAIDBETHESDA, MD, 20892, USA

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH (AN12)

Original Source

https://sam.gov/opp/9f5149fe9a04452cabb9dba2d0db66e0/view
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) through the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting proposals for the development of Radiation/Nuclear Medical Countermeasures (MCMs) and biodosimetry devices. The primary objectives are to create effective MCMs that mitigate normal tissue injuries from ionizing radiation and to advance biodosimetry tools that enhance triage and treatment strategies during radiation emergencies. This initiative is crucial for national preparedness against potential radiological incidents, as it aims to address the urgent need for medical interventions and diagnostic capabilities in mass casualty scenarios. Proposals are due by March 19, 2025, with an estimated funding of $2 million annually for successful applicants over a typical three-year contract period, totaling a possible award of $6 million. For further inquiries, interested parties may contact Albert Nguyen at nguyenal@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov.

    Point(s) of Contact
    Albert Nguyen
    nguyenal@niaid.nih.gov
    Emily Bannister
    emily.bannister@nih.gov
    Files
    Title
    Posted
    Amendment 1 - BAA-75N93024R00020.pdf
    The document is Amendment No. 1 to Solicitation No. BAA-75N93024R00020, focusing on the development of Radiation/Nuclear Medical Countermeasures (MCMs) and biodosimetry devices. It outlines funding availability and support for proposals aimed at addressing injuries from radiological events, stressing the importance of both effective treatments for radiation exposure and advanced biodosimetry tools that inform medical response strategies. Key points include a $2 million annual funding estimate for successful applicants over a typical contract period of three years, with a total possible award of $6 million. The amendment specifies that MCMs must effectively mitigate radiation injuries long after exposure, particularly for organs not covered by existing FDA-approved treatments. Additionally, it clarifies that repurposing FDA-approved drugs is encouraged and that ornation for interaction or discussions is limited to written submissions only. The overarching aim is to foster the development of innovative solutions capable of mitigating radiation effects and enhancing public health emergency preparedness in large-scale radiation incidents. Thus, the solicitation targets researchers and organizations engaged in medical countermeasures and biodosimetry, aligning with the strategic objectives of the U.S. government in protecting public health against nuclear and radiological threats.
    BAA-75N93024R00020 Development of Radiation Nuclear Medical Countermeasures (MCMs) And Biodosimetry Devices.pdf
    The solicitation outlines a Request for Proposal (RFP) from the National Institute of Allergy and Infectious Diseases (NIAID) for the development of Radiation/Nuclear Medical Countermeasures (MCMs) and biodosimetry devices. The RFP emphasizes two primary goals: creating MCMs to mitigate normal tissue injuries from ionizing radiation and advancing biodosimetry to enhance triage and treatment during radiation emergencies. Proposals must focus on one goal per submission. Submission guidelines state that proposals are due by March 19, 2025, and require registration in the System for Award Management (SAM). The estimated cost and fixed fee for the contract are to be determined (TBD). There are specific reporting requirements, including technical progress reports, which must be submitted electronically and comply with Section 508 requirements for accessibility. Key requirements include the protection of human subjects, adherence to federal regulations on financial conflicts of interest, and compliance with NIH policies promoting transparency in research. The document highlights the necessity for contractors to ensure proper handling of confidential information and human materials and mandates rigorous compliance with applicable laws. Overall, this RFP is a crucial step toward enhancing national preparedness for potential radiological emergencies.
    Presolicitation Notice BAA 75N93024R00020.pdf
    The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH under DHHS, is announcing a presolicitation for contracts focusing on the "Development of Radiation/Nuclear Medical Countermeasures (MCMs) and Biodosimetry Devices." This initiative aims to create products for assessing and treating radiation injuries from nuclear incidents, preparing them for advanced development through BARDA or the Project BioShield Act. Proposals are sought for candidate devices or MCMs aimed at diagnosing, mitigating, or treating acute radiation syndrome and delayed effects of radiation exposure, with expectations for FDA approval. Evaluation criteria include scientific rigor, technical personnel qualifications, and proposed methodologies, and are expected to span various research stages. NIAID plans to award 1-2 contracts, valued at approximately $6 million over three years, starting around March/April 2026. The submission period opens on/about December 19, 2024, and proposals must be submitted electronically via the NIAID eCPS site. This presolicitation serves the dual goals of enhancing national preparedness and advancing nuclear health technologies, reflecting the government's ongoing efforts to improve responses to public health emergencies involving radiation exposure.
    Similar Opportunities
    Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
    Buyer not available
    The Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals under the Broad Agency Announcement (BAA) BAA-23-100-SOL-00004 for advanced research and development of Medical Countermeasures (MCMs) aimed at addressing public health threats such as chemical, biological, radiological, and nuclear (CBRN) incidents, as well as emerging infectious diseases and pandemic influenza. The initiative seeks to foster public-private partnerships to enhance the development and responsiveness of life-saving MCMs, emphasizing the importance of technological maturity, regulatory compliance, and manufacturing standards in the evaluation process. This opportunity is critical for strengthening national health security and improving preparedness for future public health emergencies, with an open submission period running until September 25, 2028, at 4:30 PM Eastern Time. Interested parties can direct inquiries to BARDA-BAA@hhs.gov for further information.
    In Vitro Assessments of Antimicrobial Activity
    Buyer not available
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for the In Vitro Assessments of Antimicrobial Activity (IVAAA) program through solicitation RFP 75N93024R00024. This initiative aims to support in vitro testing to evaluate the therapeutic potential of compounds against over 270 infectious agents, facilitating the development of vaccines, therapeutics, and diagnostics for infectious diseases. The program is critical for enhancing public health preparedness and response capabilities, particularly in addressing emerging health threats such as bioterrorism and infectious diseases. Proposals are due by March 10, 2025, with a funding range of $2,500 to $15 million available through January 14, 2033. Interested parties can direct inquiries to Alexander Beraud at alexander.beraud@nih.gov or Brian Madgey at brian.madgey@nih.gov.
    AMENDMENT 0004: Reactor Recovery Services
    Buyer not available
    The Department of Commerce, through the National Institute of Standards and Technology (NIST), is soliciting proposals for an Indefinite Delivery Indefinite Quantity (IDIQ) contract focused on "Nuclear Reactor Recovery Services" at the National Bureau of Standards Reactor (NBSR) in Gaithersburg, Maryland. The contract, anticipated to span four years with a total value of up to $9 million, requires contractors to provide labor, materials, and services to address contamination issues and ensure compliance with safety regulations following elevated radiation levels. This procurement is critical for maintaining operational safety and environmental standards in nuclear research facilities, emphasizing the importance of rigorous safety protocols and qualified personnel. Interested parties must submit their proposals by 5:00 p.m. ET on March 7, 2025, and direct inquiries to Contract Specialist Cielo Ibarra at cielo.ibarra@nist.gov.
    Radiopharmaceuticals - Naval Medical Center Portsmouth
    Buyer not available
    The Department of Defense, through the Defense Health Agency, is soliciting proposals for the supply of radiopharmaceuticals to the Naval Medical Center Portsmouth. The procurement aims to secure a range of unit dose radiopharmaceuticals essential for cancer patient care, including isotopes such as Tc-99m, I-123, and F-18, with specific quantities and pricing outlined for various medical applications over multiple contract periods from 2026 to 2030. These radiopharmaceuticals play a critical role in diagnostic imaging and treatment, ensuring that healthcare providers have access to necessary medical supplies for effective patient care. Proposals are due by March 11, 2025, with inquiries accepted until February 17, 2025; interested vendors should contact Carol Uebelacker at carol.e.uebelacker.civ@health.mil or call 210-952-8111 for further details.
    DHS BROAD AGENCY ANNOUNCEMENT (BAA) RESEARCH AND DEVELOPMENT (R&D) COUNTERING WEAPONS OF MASS DESTRUCTION (CWMD)
    Buyer not available
    Solicitation: Department of Homeland Security (DHS) is seeking Research and Development (R&D) proposals for countering Weapons of Mass Destruction (CWMD). The objective is to identify, explore, and demonstrate new technologies and capabilities to prevent, protect against, respond to, and mitigate nuclear, chemical, radiological, and biological threats and incidents. This 5-year Broad Agency Announcement (BAA) will provide an acquisition tool for innovative solutions. Proposals will be accepted within specified timeframes for various Areas of Interest (AOI) outlined in the notice. Interested parties can find more information on SAM.gov.
    DHS CWMD Mobile Detection Deployment Program (MDDP) RFI
    Buyer not available
    The Department of Homeland Security (DHS) is seeking responses to a Request for Information (RFI) regarding the Mobile Detection Deployment Program (MDDP), aimed at enhancing national capabilities for detecting chemical, biological, radiological, and nuclear (CBRN) threats. The program requires contract support services, including the deployment of technical support personnel and advanced detection equipment, with a focus on maintaining detection capacity, supporting training exercises, and managing operational logistics. This initiative is critical for bolstering the nation's defenses against WMD threats and fostering collaboration among federal, state, and local entities. Interested parties must submit a capability statement by March 7, 2025, and can contact William Grimm at william.grimm@hq.dhs.gov or 202-601-9823 for further information.
    BROAD AGENCY ANNOUNCEMENT (BAA) RESEARCH AND DEVELOPMENT IN SUPPORT OF THE JOINT PROGRAM EXECUTIVE OFFICE FOR CHEMICAL, BIOLOGICAL, RADIOLOGICAL AND NUCLEAR DEFENSE (JPEO-CBRND), JPM MEDICAL AND JPL EB
    Buyer not available
    Solicitation DEPT OF DEFENSE is seeking research and development services in support of the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB. The service being procured is for the identification of the best available science in the areas of research interest, including novel solutions and improved methods for developing medical countermeasures. The government is specifically interested in enabling technologies, life cycle bioinformatics, and improved logistics tracking. The procurement notice is available on SAM.gov and the JPEO-CBD website. Potential offerors are encouraged to communicate with the JPMO technical contacts for proposal ideas. For any questions or inquiries, contact usarmy.detrick.mcs.mbx.baa@mail.mil.
    FY25 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
    Buyer not available
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is soliciting proposals through the FY25 Broad Agency Announcement (BAA) aimed at advancing regulatory science and innovation. This opportunity invites organizations, particularly small businesses, to submit research and development proposals that address critical areas such as alternative drug development methods, advanced manufacturing technologies, and predictive toxicology, with a strong emphasis on including diverse populations in research. Proposals must be submitted by February 24, 2025, and will undergo a two-tier evaluation process, with the potential for multiple contracts awarded based on proposal quality and funding availability. Interested parties can contact Ian Weiss at Ian.Weiss@fda.hhs.gov or by phone at 301-796-5728 for further information.
    ACC-APG Natick Division FY25 Upcoming Aquisitions
    Buyer not available
    The Department of Defense, through the ACC-APG Natick Division, is announcing upcoming acquisitions for Fiscal Year 2025, aimed at enhancing capabilities related to chemical, biological, radiological, and nuclear defense. The procurement includes a variety of requirements such as the purchase of a CISCO AMP firepower system, professional services, peptide synthesizers, and HVAC maintenance, with contract values ranging from $110,032 to $49,201,610. These acquisitions are crucial for supporting the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO CBRND) in its mission to ensure national security. Interested contractors can reach out to the Natick Division at usarmy.natick.acc-micc.mbx.ncd-internal-tasker@army.mil for further details, as the tentative award dates are set for early 2025.
    Research and Development Innovations Broad Agency Announcement
    Buyer not available
    The Defense Threat Reduction Agency (DTRA) is soliciting innovative research and development proposals through its Broad Agency Announcement (BAA) HDTRA1-22-S-0003, aimed at enhancing capabilities to counter weapons of mass destruction (WMD) and emerging threats. The BAA invites submissions focused on technologies at Technology Readiness Levels (TRL) 3-7, addressing detection, identification, and management of chemical, biological, nuclear, and other threats, while also encouraging operational strategies for force protection. This initiative is critical for advancing national security and fostering collaboration in defense-related research and development. Interested parties should submit their proposals in two phases, with funding potentially ranging from $500,000 to $5 million, and can direct inquiries to the BAA Program Manager at dtra.belvoir.rd.mbx.rd-baa-inbox@mail.mil. Key deadlines include the final submission date for Phase I proposals on June 16, 2023, and ongoing opportunities through 2027.